A Study to Evaluate the Evolution of Lymphocyte Count and it's Association With Progression Free Survival during Sunitinib's First Cycle of Treatment in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Trial Profile

A Study to Evaluate the Evolution of Lymphocyte Count and it's Association With Progression Free Survival during Sunitinib's First Cycle of Treatment in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 20 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top